The CDC is investigating Valneva’s (NASDAQ:VALN) chikungunya vaccine IXCHIQ following the hospitalizations of five individuals after receiving the shot.
The agency said the hospitalizations were for cardiac or neurologic events following vaccination with IXCHIQ in individuals 65 years and older.
